So, this Covid vaccine looks like it might work! In NEJM today. Double-checked it with advanced statistical analysis - and you can indeed park a bus between those curves. You know reviewer 3 still asked for a p-value though.... nejm.org/doi/full/10.10…( (. .

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients with Myelodysplastic Syndrome BMT CTN @TheBethesdaLabs @nih_nhlbi JCO Precision Oncology Laura Dillon, PhD, FACMG Gege Gui Steven Devine Mitch Horwitz Bart Scott ArcherDX, Inc. ascopubs.org/doi/abs/10.120…

Congrats Laura Dillon, PhD, FACMG Gege Gui houriganlab.com @TheBethesdaLabs BMT CTN

Spending weekend preparing my talk for big pre-tenure external review. Reflecting how proud I am of amazing work my team at houriganlab.com has done over past four years despite Covid19. Fifty publications. Two plenary + 40 other talks. 8 awards. Great post-lab jobs.

Summary of pre-alloHCT NGS testing in MDS and AML cohorts of BMT CTN 0901 clinical trial from @TheBethesdaLabs Gege Gui Laura Dillon, PhD, FACMG Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. ascopubs.org/doi/abs/10.120…

Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis bloodcancerdiscov.aacrjournals.org/content/early/…

Excited to share our work Meg Goswami Grateful for all the support from co-authors and especially our brilliant and caring mentor Chris Hourigan

From the July issue: Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid #Leukemia from Nonmalignant #ClonalHematopoiesis. #leusm #singlecell @nih_nhlbi Laura Dillon, PhD, FACMG Chris Hourigan bit.ly/3ezbuaJ

Excited for Chris Hourigan to present our latest results tomorrow at 11:45AM CT from the Pre-MEASURE study at #ASCO2022 examining #MRD in a large cohort of #AML patients prior to transplant. Stick around for the last session! #savingthebest4last bit.ly/3t0LjBe

CONGRESS #ASCO22 | Chris Hourigan NIH discusses MRD testing prior to allo-SCT for pts with AML in first remission in the Pre-MEASURE study. (N=457). NGS-MRD prior to alloHCT in AML CR1 was prognostic. #leusm #leukemia

MRD in AML was previously most useful for papers, not patients. Until now! Chris Hourigan moving us into the “getting stuff done era” with this Herculean 1075 pt study of MRD in CR1 heading to SCT. #ASCO #leusm

AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation | ASH Clinical News | American Society of Hematology ashpublications.org/ashclinicalnew…

During #ASCO2022 , the AML Hub spoke with Chris Hourigan, NIH. We asked, Can pre-transplant MRD testing predict patients who are more likely to relapse? 👉 loom.ly/DC-0-Fk 👈 #AML #AMLsm #leusm #leukemia

Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission medrxiv.org/content/10.110…

DNA Sequencing to Detect Residual Disease for Acute Myeloid Leukemia ja.ma/3JgqIBj via JAMA part of JAMA Network

Excited to finally share our work published today in JAMA! jamanetwork.com/journals/jama/…

So proud of our HouriganLab #ASH23 superstar abstract award winners - biostats PhD student ⁦Gege Gui⁩ (oral on IDH2 MRD tomorrow Sun in sess617 at 9.30am and poster on IDH1 MRD on Mon) and medical student ⁦⁦Pranay Hegde⁩ presenting TKD MRD poster tomorrow (Sun).

She crushed it! First major international talk for ⁦Gege Gui⁩ - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. ⁦@TheBethesdaLabs⁩ ⁦CIBMTR⁩ ⁦ASH⁩

Cleveland clinic medical student ⁦Cleveland Clinic⁩ ⁦Pranay Hegde⁩ presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at ⁦@TheBethesdaLabs⁩ ⁦NIH⁩ ⁦CIBMTR⁩

news.vt.edu/content/news_v…